HEPATITIS B VIRUS (HBV) INFECTION DRUG PIPELINE ANALYSIS: DEMAND FORECAST AND FUTURE OUTLOOK (2034)

The Hepatitis B Virus (HBV) infection drug pipeline analysis is a critical focus in today’s pharmaceutical and biotech sectors, driven by the increasing prevalence of HBV infections and the limitations of current treatments. Affecting over 257 million individuals globally as of 2022 and resulting in 1.5 million new cases annually, HBV remains a l